Acelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) Could Burn Your Long Portfolio After More Shorts

June 20, 2017 - By Darrin Black

 Acelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) Could Burn Your Long Portfolio After More Shorts

Investors sentiment increased to 2.06 in Q4 2016. Its up 0.84, from 1.22 in 2016Q3. It is positive, as 2 investors sold AcelRx Pharmaceuticals Inc shares while 16 reduced holdings. 15 funds opened positions while 22 raised stakes. 14.54 million shares or 6.63% less from 15.57 million shares in 2016Q3 were reported.
Blackrock Advsrs Limited has invested 0% of its portfolio in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Nationwide Fund Advsrs invested 0% of its portfolio in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Palo Alto Investors Llc stated it has 1.03M shares. Perceptive Advisors Limited Liability Co owns 1% invested in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) for 5.41 million shares. Blackrock Fund Advsrs has 1.11M shares for 0% of their portfolio. Citigroup has invested 0% in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Wells Fargo Mn holds 0% or 40,807 shares in its portfolio. Hamilton Lane Advsrs Ltd Com stated it has 12,486 shares or 0.02% of all its holdings. Geode Capital Limited Liability Co holds 219,833 shares. Cornerstone Capital owns 31,400 shares for 0.02% of their portfolio. Millennium Mngmt Limited Liability reported 178,380 shares. California State Teachers Retirement Systems reported 0% in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Bridgeway Capital Management Inc owns 281,650 shares for 0.01% of their portfolio. Granahan Inv Mngmt Ma reported 0.05% of its portfolio in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Two Sigma Ltd Liability Company accumulated 17,517 shares.

The stock of Acelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) registered an increase of 3.6% in short interest. ACRX’s total short interest was 3.72M shares in June as published by FINRA. Its up 3.6% from 3.59 million shares, reported previously. With 220,000 shares average volume, it will take short sellers 17 days to cover their ACRX’s short positions. The short interest to Acelrx Pharmaceuticals Incorporated’s float is 13.94%.

It closed at $2.5 lastly. It is down 14.24% since June 20, 2016 and is downtrending. It has underperformed by 30.94% the S&P500.

AcelRx Pharmaceuticals, Inc. is a pharmaceutical firm focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The company has market cap of $118.18 million. The Firm operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. It currently has negative earnings. The Company’s lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03.

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Ratings Coverage

Among 5 analysts covering AcelRx Pharmaceuticals (NASDAQ:ACRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AcelRx Pharmaceuticals had 11 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Buy” rating by TH Capital given on Thursday, September 15. The rating was initiated by H.C. Wainwright with “Buy” on Wednesday, September 2. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, May 3 report. The stock has “Buy” rating by TH Capital on Monday, October 5. The stock of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has “Buy” rating given on Friday, October 30 by Jefferies. The company was maintained on Monday, October 5 by Roth Capital. The stock of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) earned “Buy” rating by Seaport Global on Friday, May 6. The rating was maintained by Cowen & Co with “Hold” on Tuesday, August 4.

More notable recent AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) news were published by: which released: “BRIEF-AcelRx Pharmaceuticals reports Q1 total revenue $3.1 million” on May 08, 2017, also with their article: “AcelRx Pharmaceuticals’ ZALVISO Recognized for Innovative Design with …” published on June 01, 2017, published: “AcelRx Pharmaceuticals To Benefit From DSUVIA Launch” on May 31, 2017. More interesting news about AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) were released by: and their article: “AcelRx Pharmaceuticals’ ARX-04 Phase 3 Trial Met its Primary Endpoint, Reduced …” published on August 15, 2016 as well as‘s news article titled: “AcelRx Pharmaceuticals Unveiling Results of ARX-04 SAP303 Study in Post …” with publication date: November 17, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.